A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxycamptothecin) in Adult Patients with Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Nov 2021 According to a Vivacitas Oncology media release, data from this study presented at the Annual 5th Meridian Clinical Trials Conference.
03 May 2021 According to a Vivacitas Oncology media release, the company is collaborating with Image Analysis Group to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67 in patients with recurrent glioblastoma multiforme. The company has performed performed a retrospective analysis of imaging data from this trial.
08 Dec 2014 Planned end date changed from 1 Dec 2014 to 1 Feb 2015, according to the ClinicalTrials.gov record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com